Literature DB >> 14502284

Monitoring photodynamic therapy of solid tumors online by BOLD-contrast MRI.

Shimon Gross1, Assaf Gilead, Avigdor Scherz, Michal Neeman, Yoram Salomon.   

Abstract

Antivascular photodynamic therapy (PDT) of tumors with palladium-bacteriopheophorbide (TOOKAD) relies on in situ photosensitization of the circulating drug by local generation of cytotoxic reactive oxygen species, which leads to rapid vascular occlusion, stasis, necrosis and tumor eradication. Intravascular production of reactive oxygen species is associated with photoconsumption of O(2) and consequent evolution of paramagnetic deoxyhemoglobin. In this study we evaluate the use of blood oxygenation level-dependent (BOLD) contrast magnetic resonance imaging (MRI) for real-time monitoring of PDT efficacy. Using a solid tumor model, we show that TOOKAD-PDT generates appreciable attenuation (25-40%) of the magnetic resonance signal, solely at the illuminated tumor site. This phenomenon is independent of, though augmented by, ensuing changes in blood flow. These results were validated by immunohistochemistry and intravital microscopy. The concept of photosensitized BOLD-contrast MRI may have intraoperative applications in interactive guidance and monitoring of antivascular cancer therapy, PDT treatment of macular degeneration, interventional cardiology and possibly other biomedical disciplines.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14502284     DOI: 10.1038/nm940

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  48 in total

1.  Therapeutic Enhancement of Verteporfin-mediated Photodynamic Therapy by mTOR Inhibitors.

Authors:  Daniel Kraus; Pratheeba Palasuberniam; Bin Chen
Journal:  Photochem Photobiol       Date:  2019-12-17       Impact factor: 3.421

2.  Acute tumor response to ZD6126 assessed by intrinsic susceptibility magnetic resonance imaging.

Authors:  Simon P Robinson; Tammy L Kalber; Franklyn A Howe; Dominick J O McIntyre; John R Griffiths; David C Blakey; Lynsey Whittaker; Anderson J Ryan; John C Waterton
Journal:  Neoplasia       Date:  2005-05       Impact factor: 5.715

3.  Nanoparticles for two-photon photodynamic therapy in living cells.

Authors:  De Gao; Rodney R Agayan; Hao Xu; Martin A Philbert; Raoul Kopelman
Journal:  Nano Lett       Date:  2006-11       Impact factor: 11.189

Review 4.  Photodynamic therapy for prostate cancer--a review of current status and future promise.

Authors:  Caroline M Moore; Doug Pendse; Mark Emberton
Journal:  Nat Clin Pract Urol       Date:  2009-01

5.  Light delivery over extended time periods enhances the effectiveness of photodynamic therapy.

Authors:  Mukund Seshadri; David A Bellnier; Lurine A Vaughan; Joseph A Spernyak; Richard Mazurchuk; Thomas H Foster; Barbara W Henderson
Journal:  Clin Cancer Res       Date:  2008-05-01       Impact factor: 12.531

6.  Vascular targeted photodynamic therapy for localized prostate cancer.

Authors:  Herbert Lepor
Journal:  Rev Urol       Date:  2008

Review 7.  Functional MR Imaging Techniques in Oncology in the Era of Personalized Medicine.

Authors:  Matthias R Benz; Hebert Alberto Vargas; Evis Sala
Journal:  Magn Reson Imaging Clin N Am       Date:  2015-09-26       Impact factor: 2.266

8.  Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.

Authors:  Hiral Patel; Rosemarie Mick; Jarod Finlay; Timothy C Zhu; Elizabeth Rickter; Keith A Cengel; S Bruce Malkowicz; Stephen M Hahn; Theresa M Busch
Journal:  Clin Cancer Res       Date:  2008-08-01       Impact factor: 12.531

9.  Permanent occlusion of feeding arteries and draining veins in solid mouse tumors by vascular targeted photodynamic therapy (VTP) with Tookad.

Authors:  Noa Madar-Balakirski; Catherine Tempel-Brami; Vyacheslav Kalchenko; Ori Brenner; David Varon; Avigdor Scherz; Yoram Salomon
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

10.  Vascular-targeted photodynamic therapy with BF2-chelated Tetraaryl-Azadipyrromethene agents: a multi-modality molecular imaging approach to therapeutic assessment.

Authors:  A T Byrne; A E O'Connor; M Hall; J Murtagh; K O'Neill; K M Curran; K Mongrain; J A Rousseau; R Lecomte; S McGee; J J Callanan; D F O'Shea; W M Gallagher
Journal:  Br J Cancer       Date:  2009-10-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.